KVD900
Sponsors
Kalvista Pharmaceuticals Limited, KalVista Pharmaceuticals, Ltd.
Conditions
Hereditary AngioedemaHereditary Angioedema Type I or II
Phase 1
Phase 2
Phase 3
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II
A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II
Participating in the KVD900-302 Trial
Active, not recruitingCTIS2023-505904-41-00
Start: 2022-11-17Target: 75Updated: 2025-12-23
Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with Hereditary Angioedema Type I or II
CompletedCTIS2023-507591-44-00
Start: 2024-10-24End: 2026-01-15Target: 14Updated: 2025-12-19